Currently, available therapeutic options for DN patients are limited, which include angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and sodium-dependent glucose transporter 2 (SGLT-2) inhibitors. This evidence concerns the gene SLC5A2 and liver dysplastic nodule.